KIT and neoplasm: Some in vitro studies in SCLC demonstrate encouraging results with imatinib, both as monotherapy and in combination, showing anti-tumoural activity by inhibiting cell growth and tumour angiogenesis, particularly by inhibiting c-Kit signalling.